Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379160 | 0.92 | LMNA (0.49) | GRM2LMNAALDH1A1MAPTCYP11B1 | |
| SCHEMBL302225 | 0.90 | LMNA (0.60) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2188998 | 0.86 | ALDH1A1 (0.70) | GRM2LMNAALDH1A1CYP11B1MEN1 | |
| SCHEMBL3379839 | 0.84 | LMNA (0.56) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL301986 | 0.84 | NAMPT (0.51) | LMNAALDH1A1MAPTCYP11B1HTT | |
| SCHEMBL301861 | 0.84 | LMNA (0.49) | GRM2LMNAALDH1A1MAPTGPR132 | |
| SCHEMBL3376926 | 0.83 | MAPT (0.60) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2185822 | 0.83 | RAB9A (0.59) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3379037 | 0.81 | MAPT (0.57) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2189508 | 0.81 | HTT (0.70) | LMNAMAPTMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | claimed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | claimed |
| JP-2012500836-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2342177-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-07-13 | — | — | EP | claimed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| WO-2010023448-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-20140221337-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | disclosed |
| EP-2342177-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-07-13 | — | — | EP | disclosed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023448-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221337-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | GRM2 1468/4885LMNA 1619/4885ALDH1A1 1360/4885 |
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | GRM2 492/4885LMNA 2145/4885ALDH1A1 3795/4885 |
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | GRM2 1468/4885LMNA 1619/4885ALDH1A1 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.